Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Epidermal Growth Factor Receptor
97%
Colorectal Carcinoma
83%
Neoplasm
73%
Epidermal Growth Factor Receptor Kinase Inhibitor
62%
Monoclonal Antibody
52%
Clinical Trial
41%
Diseases
36%
Cetuximab
36%
Non Small Cell Lung Cancer
33%
Chemotherapy
31%
Vasculotropin
30%
Metastatic Colorectal Cancer
29%
Vandetanib
22%
Solid Malignant Neoplasm
21%
Bortezomib
20%
Angiogenesis Inhibitor
20%
Glycan
20%
Immunotherapy
20%
Lung Cancer
20%
Erlotinib
18%
Overall Survival
18%
Vasculotropin Receptor
17%
Antitumor Activity
17%
Cancer Model
15%
Colon Carcinoma
14%
Tumor Growth
14%
Cytotoxic Agent
14%
Gefitinib
13%
Proteasome
12%
Bevacizumab
12%
Selumetinib
10%
Receptor
10%
Sorafenib
10%
Small Interfering RNA
10%
Cyclophosphamide
10%
Vasculotropin Receptor 1
10%
Volume of Distribution
10%
Colorectal Tumor
10%
Cediranib
10%
Ovary Cancer
10%
Circulating Tumor DNA
10%
Histone Deacetylase
10%
Adenosine Phosphate
10%
Protein Arginine Methyltransferase
10%
Fluorouracil
10%
Vorinostat
10%
Proteasome Inhibitor
10%
Clinical Pharmacokinetics
10%
Antiangiogenic
10%
Keyphrases
Epidermal Growth Factor Receptor Inhibitors
54%
Epidermal Growth Factor Receptor
50%
Anti-EGFR
34%
Metastatic Colorectal Cancer (mCRC)
30%
Cancer Cells
27%
Monoclonal Antibody
26%
Vascular Endothelial Growth Factor
25%
Vascular Endothelial Growth Factor Receptor (VEGFR)
24%
Cetuximab
24%
Antitumor Activity
24%
Non-small Cell Lung Cancer (NSCLC)
23%
Overall Survival
21%
Microsatellite Stable Colorectal Cancer
20%
Disease Control
20%
Antiproliferative Activity
20%
Immune Checkpoint Blockade
20%
Treatment Termination
20%
Targeted Agents
20%
NEO-201
20%
Erlotinib
20%
Cancer Cell Lines
19%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
16%
Cancer Treatment
15%
Immune Checkpoint Inhibitors
14%
Clinical Trials
13%
Receptor Blocking
13%
Cytotoxic Drugs
13%
Small Molecules
13%
Colorectal Cancer
12%
Gefitinib
12%
Growth Factor Pathway
12%
ZD6474
12%
Autocrine Signaling
12%
Confidence Interval
11%
Colorectal Cancer Cells
10%
Combined Therapy
10%
Stereotactic Body Radiation Therapy
10%
AZD2171
10%
Sequence-dependent
10%
Target-guided
10%
Anticancer Therapy
10%
Acquired Resistance
10%
Bortezomib
10%
Survival Improvement
10%
Sorafenib
10%
Immune-related Adverse Events
10%
Growth Factor Receptor Tyrosine Kinase
10%
MET Amplification
10%
Cediranib
10%
Antiangiogenic Agents
10%
Medicine and Dentistry
Colorectal Carcinoma
51%
Epidermal Growth Factor Receptor
40%
Neoplasm
40%
Vasculotropin
30%
Malignant Neoplasm
27%
Monoclonal Antibody
26%
Diseases
26%
Tumor Cell
24%
Cancer Therapy
24%
Immunotherapy
23%
Microsatellite Instability
21%
Angiogenesis Inhibitor
20%
Immune Checkpoint Blockade
20%
Cancer Cell Line
20%
Anti-Epidermal Growth Factor Receptor
20%
Metastatic Colorectal Cancer
20%
Overall Survival
19%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Cancer Model
16%
Vasculotropin Receptor
14%
Biological Marker
14%
Antineoplastic Activity
13%
Cancer Treatment
13%
Clinical Trial
13%
Bevacizumab
12%
Immune Checkpoint Inhibitor
12%
Cancer Cell
12%
Immunity
11%
Signal Transduction Inhibitor
10%
Vasculotropin Receptor 1
10%
Selumetinib
10%
Antiangiogenic
10%
Angiogenesis
10%
Xenograft
10%
Cytotoxicity
10%
Ticilimumab
10%
Immune-Related Adverse Events
10%
Cediranib
10%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 1
10%
Histone Deacetylase
10%
Small Interfering RNA
10%
Bortezomib
10%
Vorinostat
10%
Autoimmunity
10%
Lymphocyte
10%
Intensity Modulated Radiation Therapy
10%
Gastrointestinal Cancer
10%
Belinostat
10%
Microwave Thermotherapy
10%
Rectum Cancer
10%